文献速递垂体与肾上腺疾病

精氨酸加压素缺乏(中枢性尿崩症)患者对MDMA激发试验的催产素反应:单中心病例对照研究及嵌套随机双盲安慰剂对照交叉试验

Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2023-05-13

这项单中心病例对照研究嵌套随机双盲安慰剂对照交叉试验,纳入15例精氨酸加压素缺乏(中枢性尿崩症)患者和15名健康对照,使用MDMA(100 mg)作为催产素能系统激发试验。结果显示健康对照血浆催产素AUC较患者高82%(95%CI 70-186),差异为85 678 pg/mL(95%CI 63 356-108 000,p<0.0001),患者主观效应轻微,提示患者存在有临床意义的催产素缺乏。

要点

  • 健康对照MDMA后催产素AUC为102 095 pg/mL(41 782-129 565),患者为6446 pg/mL(1291-11 577)。
  • 健康对照催产素AUC较患者高82%(95%CI 70-186),差异85 678 pg/mL(p<0.0001)。
  • 患者仅见轻微主观效应,与催产素缺乏一致;常见不良事件为疲劳、食欲缺乏、注意力不集中和口干。

核心结论

  • 这些发现高度提示精氨酸加压素缺乏(中枢性尿崩症)患者存在有临床意义的催产素缺乏,为一种新的下丘脑-垂体疾病实体奠定基础。

研究设计与样本

  • 单中心病例对照研究,嵌套随机双盲安慰剂对照交叉试验,在瑞士巴塞尔大学医院开展。
  • 纳入15例精氨酸加压素缺乏(中枢性尿崩症)患者和15名健康对照,按年龄、性别和BMI 1:1匹配。
  • 采用区组随机化分配参与者首次实验 session 接受单次口服MDMA(100 mg)或安慰剂,下次 session 接受相反处理,两次 session 间洗脱期至少2周。
  • 参与者和评估结局的研究者对分组设盲;在MDMA或安慰剂后0、90、120、150、180和300分钟测量催产素浓度。

主要发现

  • 健康对照基线血浆催产素中位浓度为77 pg/mL(IQR 59-94),MDMA后增加659 pg/mL(355-914),AUC为102 095 pg/mL(41 782-129 565)。
  • 患者基线催产素浓度为60 pg/mL(51-74),MDMA后仅轻度增加66 pg/mL(16-94),AUC为6446 pg/mL(1291-11 577)。
  • 健康对照的催产素AUC较患者高82%(95% CI 70-186),差异为85 678 pg/mL(95% CI 63 356-108 000,p<0.0001)。
  • 健康对照催产素增加伴随典型强烈的亲社会、共情和抗焦虑主观效应,而患者仅观察到轻微主观效应。
  • 最常见不良事件为疲劳(健康对照8例[53%] vs 患者8例[53%])、食欲缺乏(10例[67%] vs 8例[53%])、注意力不集中(8例[53%] vs 7例[47%])和口干(8例[53%] vs 8例[53%]);健康对照2例(13%)和患者4例(27%)出现短暂轻度低钾血症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Disruptions of the hypothalamic-pituitary axis can cause an arginine vasopressin deficiency, also known as central diabetes insipidus. Patients with this condition are at high risk of additional oxytocin deficiency owing to the close anatomical proximity of oxytocin-producing neurons; however, no conclusive evidence for such a deficiency has been reported. We aimed to use 3,4-methylenedioxymethamphetamine (MDMA, also known as ecstasy), a strong activator of the central oxytocinergic system, as a biochemical and psychoactive provocation test to investigate oxytocin deficiency in patients with arginine vasopressin deficiency (central diabetes insipidus). METHODS: This single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial included patients with arginine vasopressin deficiency (central diabetes insipidus) and healthy controls (matched 1:1 by age, sex, and BMI) and was conducted at the University Hospital Basel, Basel, Switzerland. We used block randomisation to assign participants to receive either a single oral dose of MDMA (100 mg) or placebo in the first experimental session; patients received the opposite treatment at the next session, with a wash-out period of at least 2 weeks between the two sessions. Participants and investigators assessing the outcomes were masked to assignment. Oxytocin concentrations were measured at 0, 90, 120, 150, 180, and 300 min after MDMA or placebo. The primary outcome was the area under the plasma oxytocin concentration curve (AUC) after drug intake. The AUC was compared between groups and conditions using a linear mixed-effects model. Subjective drug effects were assessed throughout the study using ten-point visual analogue scales. Acute adverse effects were assessed before and 360 min after drug intake using a 66-item list of complaints. This trial is registered with ClinicalTrials.gov, NCT04648137. FINDINGS: Between Feb 1, 2021, and May 1, 2022, we recruited 15 patients with arginine vasopressin deficiency (central diabetes insipidus) and 15 healthy controls. All participants completed the study and were included in the analyses. In healthy controls, median plasma oxytocin concentration was 77 pg/mL (IQR 59-94) at baseline and increased by 659 pg/mL (355-914) in response to MDMA, resulting in an AUC of 102 095 pg/mL (41 782-129 565); in patients, baseline oxytocin concentration was 60 pg/mL (51-74) and only slightly increased by 66 pg/mL (16-94) in response to MDMA, resulting in an AUC of 6446 pg/mL (1291-11 577). The effect of MDMA on oxytocin was significantly different between groups: the AUC for oxytocin was 82% (95% CI 70-186) higher in healthy controls than in patients (difference 85 678 pg/mL [95% CI 63 356-108 000], p<0·0001). The increase in oxytocin in healthy controls was associated with typical strong subjective prosocial, empathic, and anxiolytic effects, whereas only minimal subjective effects were observed in patients, in agreement with the lack of increase in oxytocin concentrations. The most frequently reported adverse effects were fatigue (eight [53%] healthy controls and eight [53%] patients), lack of appetite (ten [67%] healthy controls and eight [53%] patients), lack of concentration (eight [53%] healthy controls and seven [47%] patients), and dry mouth (eight [53%] healthy controls and eight [53%] patients). In addition, two (13%) healthy controls and four (27%) patients developed transient mild hypokalaemia. INTERPRETATION: These findings are highly suggestive of clinically meaningful oxytocin deficiency in patients with arginine vasopressin deficiency (central diabetes insipidus), laying the groundwork for a new hypothalamic-pituitary disease entity. FUNDING: Swiss National Science Foundation, Swiss Academy of Medical Sciences, and the G&J Bangerter-Rhyner Foundation.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Atila C, Holze F, Murugesu R, et al. Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial. Lancet Diabetes Endocrinol. 2023. PMID: 37192642. doi:10.1016/S2213-8587(23)00120-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。